With primary liver cancer often diagnosed too late for surgery, systemic treatments are becoming vital. The review highlights advances in molecular targeted therapies and immunotherapies, including cutting-edge combinations that suppress disease progression, extend survival, and enhance quality of life for patients. Challenges in implementation remain, but the evolving landscape of systemic therapies promises new avenues for better outcomes in advanced liver cancer management.
Review by Li CB, Ning YT (…) Luo G et 3 al. in World J Hepatol
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.